 Heres a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks Biotech Stocks Hitting 52-week Highs July 13 Altimmune Inc NASDAQ: ALT announced positive preclinical data for its intranasal vaccine candidate AdCOVID argenx SE - ADR NASDAQ: ARGX Axonics Modulation Technologies Inc NASDAQ: AXNX reacted to preliminary second-quarter results Beigene Ltd NASDAQ: BGNE - announced 421 million in additional investment by Amgen, Inc. NASDAQ: AMGN in a 2.1-billion direct offering by the Chinese biotech BioMarin Pharmaceutical Inc. NASDAQ: BMRN Biondvax Pharmaceuticals Ltd - ADR NASDAQ: BVXV Brainstorm Cell Therapeutics Inc NASDAQ: BCLI Catalent Inc NYSE: CTLT DexCom, Inc. NASDAQ: DXCM Equillium Inc NASDAQ: EQ announced positive results for COVID-19 study of the drug it is co-developing with Indias Biocon Fulgent Genetics Inc NASDAQ: FLGT GENMAB ASS ADR NASDAQ: GMAB Heat Biologics Inc NASDAQ: HTBX Hologic, Inc. NASDAQ: HOLX I-Mab ADR NASDAQ: IMAB Inari Medical Inc NASDAQ: NARI ITAMAR MED LTDS ADR NASDAQ: ITMR Meridian Bioscience, Inc. NASDAQ: VIVO Novavax, Inc. NASDAQ: NVAX Pacira Biosciences Inc NASDAQ: PCRX Quidel Corporation NASDAQ: QDEL TFF Pharmaceuticals Inc NASDAQ: TFF TIZIANA LF SCIES ADR NASDAQ: TLSA West Pharmaceutical Services Inc. NYSE: WSTDown In The Dumps Biotech Stocks Hitting 52-week Lows July 13 ADiTx Therapeutics Inc NASDAQ: ADTX Generation Bio Co NASDAQ: GBIO Gritstone Oncology Inc NASDAQ: GRTS reacted to Phase 1 readouts of its cancer vaccine candidates INVENTIVA SAADR NASDAQ: IVA went public Friday NextCure Inc NASDAQ: NXTC said it is pulling the plug on NC318 monotherapy study in non-small cell lung and ovarian cancers, and the departure of its chief medical officer ORIC Pharmaceuticals Inc NASDAQ: ORIC Poseida Therapeutics, Inc. NASDAQ: PSTX went public Friday Recro Pharma Inc NASDAQ: REPH Repare Therapeutics Inc NASDAQ: RPTX Sonnet Biotherapeutics Holdings Inc NASDAQ: SONN VIVUS, Inc. NASDAQ: VVUSStocks In Focus Blueprint Out-Licenses Late-Stage Cancer Drug To Roche For Up To 1.7B Blueprint Medicines Corp NASDAQ: BPMC and Roche Holdings AG Basel ADR Common Stock OTC: RHHBY announced a licensing agreement in which Blueprint will provide exclusive rights to Roche for global co-development and commercialization of pralsetinib outside the U.S., excluding Greater China. Prasetinib is Blueprints investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancer, as well as other solid tumours.The companies also said they plan to expand development of pralsetinib in multiple treatment settings and explore development of a next-generation RET inhibitor under the collaboration.The agreement provides for Blueprint receiving an upfront cash payment of 675 million and a 100-million equity investment. In addition, Blueprint is eligible to receive up to 927 million in contingent development, regulatory and sales-based milestones, and royalties on net product sales outside the U.S.In premarket trading Tuesday, Blueprint shares were jumping 9.59 to 84.FDA Allows Expanded Access To Single Patient For Vandas Gastroparesis Investigational Therapy Vanda Pharmaceuticals Inc. NASDAQ: VNDA said the FDA has allowed a single patient in an Individual Patient Expanded Access protocol, enabling access to continued treatment with tradipitant for gastroparesis beyond the 12 weeks of a Phase 3 study in which he originally participated. The company said the treating physician had judged tradipitant was the only treatment that effectively managed the patients gastroparesis symptoms.The stock was up 11.8 premarket at 12.70.Eisai, Biogen Begin Late-Stage Study Of Drug To Treat Preclinical Alzheimers The Alzheimers Clinical Trials Consortium, along with Biogen Inc NASDAQ: BIIB and Eisai Co., Ltd OTC: ESALY said a new Phase 3 clinical study -- dubbed AHEAD 3-45 -- of BAN2401, an anti-amyloid beta protofibril antibody, has been initiated in the U.S. for individuals with preclinical Alzheimers disease.Such patients, according to the companies, are clinically normal and have intermediate or elevated levels of amyloid in their brains. BAN2401 is being studied in a pivotal Phase 3 clinical study in symptomatic early Alzheimers disease.The AHEAD 3-45 will be conducted in the U.S., Japan, Canada, Australia, Singapore and Europe, the companies said.See also: The Week Ahead In Biotech: JJ; Kickstarts Pharma Earnings, Repare Therapeutics IPO Edwards Lifesciences, Abbott Settle Patent Heart Valve Repair Lawsuits Edwards Lifesciences Corp NYSE: EW said it has reached an agreement with Abbott Laboratories NYSE: ABT to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products.Although the companies said the settlement terms are confidential, Edwards Lifesciences said it will record a one-time settlement expense in the quarter ended June 30 and incur royalty expenses through May 2024.Edwards shares were up 1.95 to 68.50 and Abbott was up 0.89 at 93.92 premarket. Immunomedics, Roche Expand Cancer Drug Collaboration Immunomedics, Inc. NASDAQ: IMMU announced an extension of its clinical collaboration with Roche to evaluate Trodelvy, the formers anti-Trop-2 antibody-drug-conjugate, in combination with Tecentriq, the latters PD-L1-blocking checkpoint inhibitor, in patients with metastatic urothelial cancer and metastatic non-small cell lung cancer.Immunomedics shares were up 2.08 at 40.80 at the time of publication.INmune Reports Positive Early Readout For Alzheimers Drug INmune Bio Inc NASDAQ: INMB reported interim data from its Phase 1b clinical study of its lead drug XPro1595 in Alzheimers disease, with the data demonstrating XPro1595 decreased neuroinflammation in patients with Alzheimers disease.XPro1595 decreased white matter free water, a biomarker of neuroinflammation measured by MRI, the company said. Not only do we see a clear reduction in neuroinflammation, but we also know where in the brain this is occurring, which may inform us on the domains of cognition that might be affected, said CJ Barnum, director of neuroscience at INmune.The stock was jumping 65.54 premarket to 14.65. Verricas Viral Skin Infection Drug Rejected By FDA Verrica Pharmaceuticals Inc NASDAQ: VRCA said the FDA issued a Complete Response Letter regarding the NDA for VP-102, its investigational, proprietary drug-device combination for the treatment of molluscum contagiosum.The company said the CRL required additional chemistry, manufacturing and controls and human factors information, but did not raise any safety or efficacy issues.The decision was expected, as the FDA had previously issued a letter noting deficiencies that precluded discussion of labeling and post-marketing requirementscommitments.The stock was slipping 16.36 to 7.36 in premarket trading Tuesday.VolitionRx Reports Positive Clinical Trial Results For Prognostic COVID-19 Test VolitionRX Ltd NYSE: VNRX announced results from two proof-of-concept clinical studies using its Nu.Q assays, with the test showing correlation with more severe COVID-19 cases, implying strong prognostic potential.The company said it is now focused on the completion of larger longitudinal studies that would be needed to support a potential COVID-19 product launch.The stock was soaring 72.86 to 6.05 in premarket trading.Galera Completes Patient Enrollment In Phase 1b2a Pancreatic Cancer Study Galera Therapeutics Inc NASDAQ: GRTX said it has completed patient enrollment in its pilot Phase 1b2a safety and anti-cancer efficacy clinical trial of avasopasem manganese, codenamed GC4419, in combination with stereotactic body radiation therapy, in patients with locally advanced pancreatic cancer.Offerings Osmotica Pharmaceuticals PLC NASDAQ: OSMT announced the commencement of a proposed public offering of 5 million ordinary shares. All of the shares are being offered by the company.The stock was falling 17.62 premarket to 6.36.Altimmune said it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock. All of the securities in the offering will be sold by the company.The stock was trading up 8 at 27 premarket Tuesday.On The Radar Adcom Meetings The FDAs Oncologic Drugs Advisory Committee will discuss GlaxoSmithKline plcs NYSE: GSK biologic license application for belantamab mafodotin for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The drug linker technology for the product candidate was licensed from Seattle Genetics, Inc. NASDAQ: SGEN.Related Link: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates See more from Benzinga The Week Ahead In Biotech: JJ; Kickstarts Pharma Earnings, Relay Therapeutics IPO The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergans Botox Gets Label Expansion, 3 IPOs The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBioC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 